Silodosin|赛洛多辛|西洛多辛|160970-54-7

产品描述

等级：活性药物成分（API）

化学名称：1-（3-羟丙基）-5-[(2R)-2-[2-[2-（2,2,2-三氟乙氧基）苯氧基]乙胺]丙基]-2,3-二氢吲哚-7-羧酰胺

分子式：C25H32F3N3O4

分子量:495.534

外观:粉

总杂质：不大于0.5%

纯度：不低于99%

残留溶剂：完全符合ICH Q3C要求

致突变杂质：完全符合ICH M8

亚硝胺评估：可用

粒度：可根据客户要求进行普通级或研磨/筛分。

储存方法：室温

生产能力：商用

标准包装：1kg/袋，5kg/袋，或根据客户要求

产品用途

西洛多辛API是一种选择性前列腺受体的a1A肾上腺素受体（a1A- ar）拮抗剂，作为一种口服治疗良性前列腺肥大（BPH）相关排尿困难的药物推出。膀胱颈部和前列腺平滑肌张力的调节被认为主要由a1A-AR介导。阻断这些受体会导致这些区域的平滑肌松弛，从而改善症状和尿流量。相反，a1B-AR主要位于血管平滑肌，这些受体的拮抗可导致组织松弛，并可能降低参与调节血压的心脏代偿机制。

联系方式

四川青木制药有限公司

四川省眉山市东坡区经济开发区东区顺江大道南段55号

国际营销部(International):

Email: sales@eastonpharma.cn 

Tel: 028-87827187

国内营销部(Mainland)：

李经理 13880480517   

杨经理 15982276454

Product Description

·       Grade: Active Pharmaceutical Ingredient(API)

·       Chemical Name: 1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide

·       Molecular Formula: C25H32F3N3O4

·       Molecular Weight:495.534

·       Specification: JP

·       Appearance: Powder

·       Total impurities: not more than 0.5%

·       Purity: not less than 99%

·       Residual Solvents: fully comply with ICH Q3C

·       Mutagenic impurities: fully comply with ICH M8

·       Nitrosamine assessment: available

·       Particle size: regular grade or milling/sieving according to customer’s requirement.

·       Storage: Room temperature

·       Production capacity: Commercial

·       Standard Package: 1kg/bag, 5kg/bag, or according to the customer’s requirement

·        

Applications 

·       Ruxolitinib phosphate is a phosphate salt obtained by the reaction of ruxolitinib with one equivalent of phosphoric acid.

·       Silodosin API, an a1A adrenoceptor (a1A-AR) antagonist selective for prostatic receptors, was launched as an oral treatment for dysuria associated with benign prostatic hypertrophy (BPH). The regulation of smooth muscle tone in the bladder neck and prostate is thought to be primarily mediated by a1A-AR. Blockade of these receptors can cause smooth muscle relaxation in these areas, resulting in improved symptoms and urinary flow rates. Conversely, a1B-AR is largely located on vascular smooth muscle, and antagonism of these receptors can cause tissue relaxation and potentially decrease cardiac compensation mechanisms involved in regulating blood pressure.

·        

Contact Information

Sichuan Qingmu Pharmaceutical Co., Ltd.

Add: No. 55, South Shunjiang Avenue, East Economic Development Zone, Dongpo District, Meishan City, Sichuan, 620036, China

International Marketing Department: 

Email: sales@eastonpharma.cn 

Tel: 0086-28-87827187